Literature DB >> 33991255

Role of therapeutic apheresis in the treatment of pediatric kidney diseases.

Shweta Shah1, Catherine Joseph2, Poyyapakkam Srivaths2.   

Abstract

Therapeutic apheresis utilizes apheresis procedures in the treatment of a variety of conditions including kidney disease. Therapeutic plasma exchange (TPE) is the most common modality employed with the rationale of rapid reduction of a pathogenic substance distributed primarily in the intravascular compartment; however other techniques which adsorb such pathogenic substances or alter the immune profile have been utilized in diseases affecting native and transplanted kidneys. This article discusses the modalities and technical details of therapeutic apheresis and summarizes its role in individual diseases affecting the kidney. Complications related to pediatric apheresis procedures and specifically related to apheresis in kidney disease are also discussed. Though therapeutic apheresis modalities are employed frequently in children with kidney disease, most experiences are extrapolated from adult studies. International and national registries need to be established to elucidate the role of apheresis modalities in children with kidney disease.
© 2021. IPNA.

Entities:  

Keywords:  Apheresis - Pediatric - Renal diseases

Mesh:

Year:  2021        PMID: 33991255     DOI: 10.1007/s00467-021-05093-w

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  81 in total

Review 1.  Rationales for therapeutic apheresis.

Authors:  Bruce C McLeod
Journal:  Hematology       Date:  2005       Impact factor: 2.269

2.  Therapeutic plasma exchange: core curriculum 2008.

Authors:  Andre A Kaplan
Journal:  Am J Kidney Dis       Date:  2008-06-17       Impact factor: 8.860

Review 3.  Therapeutic apheresis: a review of complications and recommendations for prevention and management.

Authors:  Michele H Mokrzycki; Rasheed A Balogun
Journal:  J Clin Apher       Date:  2011-09-05       Impact factor: 2.821

4.  Apheresis education in pathology residency.

Authors:  Alexis R Peedin; Yara A Park; Jay S Raval
Journal:  J Clin Apher       Date:  2017-05-09       Impact factor: 2.821

5.  Epidemiology of therapeutic apheresis with a multidisciplinary approach at a high volume pediatric center.

Authors:  Rachel M Sirignano; Matthew L Paden; Ross Fasano; Erin K Meyer
Journal:  J Clin Apher       Date:  2017-11-15       Impact factor: 2.821

6.  Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience.

Authors:  Helmut Schinzel; Karin Berghoff; Ingrid Beuermann; Oliver Sauer; Marc-Alexander von Mach; Ludwig Sacha Weilemann
Journal:  Transfusion       Date:  2006-04       Impact factor: 3.157

7.  Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis.

Authors:  Robert A DeSimone; Gary D Myers; Erin M Guest; Patricia A Shi
Journal:  J Clin Apher       Date:  2018-11-29       Impact factor: 2.821

8.  Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia.

Authors:  S Yokoyama; R Hayashi; M Satani; A Yamamoto
Journal:  Arteriosclerosis       Date:  1985 Nov-Dec

9.  Complications of apheresis in children.

Authors:  Bruno Michon; Albert Moghrabi; Rochelle Winikoff; Stéphane Barrette; Mark L Bernstein; Josette Champagne; Michèle David; Michel Duval; Heather A Hume; Nancy Robitaille; André Bélisle; Martin A Champagne
Journal:  Transfusion       Date:  2007-10       Impact factor: 3.157

10.  World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry.

Authors:  Volker Witt; Bernd Stegmayr; Jan Ptak; Björn Wikström; Gösta Berlin; C G Axelsson; A Griskevicius; Paolo Emilio Centoni; Giancarlo Maria Liumbruno; Pietra Molfettini; Judita Audzijoniene; K Mokvist; B Nilsson Sojka; Rut Norda; W Ramlow; Milan Blaha; M Evergren; J Tomaz
Journal:  Transfus Apher Sci       Date:  2008-11-14       Impact factor: 1.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.